Departmentof Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan.
To investigate the presence of manserin in human prostate cancers and to correlate manserin expression with pathologic outcomes and progression-free survival.
Eighty-seven patients with recent prostate cancer were classified into 4 groups based on Gleason score, and manserin immunohistochemistry was correlated with Gleason sum grade. To investigate the validity of manserin as a prognostic factor, the Cox proportional hazards regression model was performed on 48 patients in our cohort with T3 or T4 prostate cancer who were initially treated with androgen deprivation therapy.
The manserin-positive rates of patients with Gleason sums of 6, 7, 8, and ≥9 were 0%, 20.0%, 35.0%, and 48.1%, respectively. Manserin-positive rates were positively correlated with Gleason sums (P = 0.0001). Median times to cancer progression in groups with (n = 8) and without (n = 40) manserin expression were 8 months and 28 months, respectively (P = 0.01). Univariate Cox analysis revealed that manserin expression, clinical stage T4, and high Gleason sum were significantly associated with progression. Multivariate analysis revealed that only 2 factors, manserin expression (hazard ratio (HR) 4.99, P = 0.01) and clinical stage T4 (HR 4.77, P = 0.03), were independent risk factors for progression.
This is the first report of manserin expression in human prostate cancers. Manserin may serve as a marker of prostate cancer progression.
Written by:
Nishikawa K, Soga N, Ishii K, Kato M, Iwamoto Y, Hori Y, Etoh M, Ohkawara T, Yamada T, Uchida K, Kise H, Arima K, Narita M, Shiraishi T, Sugimura Y. Are you the author?
Reference: Urol Oncol. 2011 Jul 29. Epub ahead of print.
doi: 10.1016/j.urolonc.2011.06.010
PubMed Abstract
PMID: 21803620
UroToday.com Prostate Cancer Section
